tapentadol and Renal-Insufficiency

tapentadol has been researched along with Renal-Insufficiency* in 2 studies

Reviews

2 review(s) available for tapentadol and Renal-Insufficiency

ArticleYear
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.
    Drugs, 2021, Volume: 81, Issue:11

    We conducted a narrative review of the literature to compare the pharmacological, efficacy and safety profiles of tapentadol and tramadol, and to assess the clinical interest of tapentadol in adult patients. Tapentadol and tramadol share a mixed mechanism of action, including both mu-agonist and monoaminergic properties. Tapentadol is approximately two to three times more potent than tramadol and two to three times less potent than morphine. It has no identified analgesically active metabolite and is not significantly metabolised by cytochrome P450 enzymes, thus overcoming some limitations of tramadol, including the potential for pharmacokinetic drug-drug interactions and interindividual variability due to genetic polymorphisms of cytochrome P450 enzymes. The toxicity profiles of tramadol and tapentadol are similar; however tapentadol is likely to result in less exposure to serotoninergic adverse effects (nausea, vomiting, hypoglycaemia) but cause more opioid adverse effects (constipation, respiratory depression, abuse) than tramadol. The safety of tapentadol in real-world conditions remains poorly documented, particularly in at-risk patient subgroups and also in the ability to assess the risk associated with its residual serotonergic activity (serotonin syndrome, seizures). Because of an earlier market introduction, more real-world safety data are available for tramadol, including data from at-risk patient subgroups. The level of evidence on the efficacy of both tramadol and tapentadol for the treatment of chronic pain is globally low. The trials published to date show overall that tapentadol does not provide a clinically significant analgesic improvement compared to existing treatments, for which the safety profile is much better known. In conclusion, tapentadol is not a first-line opioid but represents an additional analgesic in the therapeutic choices, which some patients may benefit from after careful examination of their clinical situation, co-morbidities and co-medications.

    Topics: Analgesics, Opioid; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Humans; Liver Failure; Pain; Renal Insufficiency; Tapentadol; Tramadol

2021
[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
    Acta medica portuguesa, 2019, May-31, Volume: 32, Issue:5

    All health professionals should be aware of the importance of evaluating pain - fifth vital sign- in cancer patients. Peripheral and central acting analgesics are widely used to treat moderate to severe pain, particularly cancer pain. Many guidelines have addressed this issue. However, real life patients' have other problems and comorbidities that may raise doubts when prescribing.. Authors made a literature search, trying to clarify same specific situations: loss of oral route, renal impairment (hemodialysis), hepatic impairment, frequent opiod interactions and the availability of short-acting formulations.. The following medicines were included in this analysis: the natural opiates (morphine and codeine), their synthetic and semisynthetic derivatives (hydromorphone, oxycodone, and fentanyl), the partial agonist buprenorphine and finally tramadol and tapentadol. Transdermal systems are only available for buprenorphine and fentanyl. In hepatic impairment, fentanyl is safe, but with the exception of codeine and tramadol; other opioids should be used with caution. In renal failure: fentanyl, hydromorphone, and tapentadol are safe. Morphine should be avoided; other opioids should be used with caution. In hemodialysis, buprenorphine, fentanyl, hydromorphone and tramadol (at doses up to 200 mg/day) may be used.. Failure to recognize the impact of various situations described throughout this work, including the bioavailability due to loss of oral route, due to pharmacokinetics and pharmacodynamics of the various drugs, either in the context of the impaired metabolism or excretion, or in due to pharmacological interactions, conditions a serious risk of subtreatment of pain and consequent impact in terms of quality of life.. Opioid prescription is safe and effective, even in moderate to severe comorbidities such as renal and hepatic impairment and in patients with no oral route available. In this case, as when considering pharmacological interactions, an individualized therapeutic plan is the best solution and the patient should be assessed regularly. Unadjusted doses may relate to bad pain control and a higher prevalence of adverse events.. Introdução: A dor é equiparada a quinto sinal vital e deve ser avaliada de forma sistemática em todas as consultas de um paciente com cancro. Os fármacos utilizados na prática oncológica para tratar os doentes com dor crónica moderada a severa incluem analgésicos de ação periférica e central que têm sido abordados em múltiplas diretrizes nacionais e internacionais. No entanto, na prática clínica há que equacionar outros problemas e eventuais comorbilidades, que podem levantar dúvidas no momento da prescrição.Material e Métodos: Fez-se uma revisão da literatura, tentando refletir sobre algumas situações específicas na utilização de opióides, nomeadamente perda da via oral, insuficiência renal (hemodiálise), insuficiência hepática, interações medicamentosas e formulações de ação imediata.Resultados: Os opiáceos naturais (morfina e codeína) e os seus derivados sintéticos e semissintéticos (hidromorfona, oxicodona, fentanilo), o agonista parcial buprenorfina e finalmente o tramadol e tapentadol foram selecionados para esta análise. Os sistemas transdérmicos estão apenas disponíveis para a buprenorfina e o fentanilo. Na insuficiência hepática, o fentanilo foi considerado seguro, mascom exceção da codeína e do tramadol, podem todos ser usados com precaução. Na insuficiência renal, o fentanilo, a hidromorfona e o tapentadol foram considerados seguros. Deve evitar-se a morfina, e os restantes poderão ser usados com precaução. Em pacientes em hemodiálise pode usar-se buprenorfina, fentanilo, hidromorfona e tramadol (em doses até 200 mg/dia).Discussão: O não reconhecimento do impacto das várias situações descritas ao longo deste trabalho, nomeadamente a alteração da biodisponibilidade por perda de via oral, por alteração da farmacocinética e farmacodinâmica dos vários fármacos, quer no contexto da insuficiência de órgão responsável pelo metabolismo ou excreção, quer no contexto das interações farmacológicas, condiciona umnorme risco de subtratamento da dor e consequente impacto em termos de qualidade de vida.Conclusão: A prescrição de opióides é segura e efetiva, mesmo em situações de comorbilidades moderadas a graves como insuficiência renal e hepática e em doentes sem via oral disponível. Neste caso, como quando considerámos as interações farmacológicas, o plano terapêutico deve ser individualizado e o paciente deve ser avaliado regularmente. A seleção inadequada e/ou dose mal ajustada de um fármaco, o não reconhecimento do impacto dos efeitos adversos, frequente

    Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Cancer Pain; Codeine; Deglutition Disorders; Fentanyl; Humans; Hydromorphone; Liver Failure; Morphine; Oxycodone; Renal Dialysis; Renal Insufficiency; Tapentadol; Tramadol

2019